La Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II) in Italy for Compassionate Use in Patients with Septic Shock Associated with COVID-19
March 13, 2020 08:00 ET
|
La Jolla Pharmaceutical Company
SAN DIEGO, March 13, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve...
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2019
March 02, 2020 08:30 ET
|
La Jolla Pharmaceutical Company
SAN DIEGO, March 02, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve...
La Jolla Pharmaceutical Company Announces Preliminary GIAPREZA™ (Angiotensin II) Net Sales for the Three and Twelve Months Ended December 31, 2019
January 09, 2020 08:00 ET
|
La Jolla Pharmaceutical Company
SAN DIEGO, Jan. 09, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to...
La Jolla to Reassess Continued Development of LJPC-401 Based on Recent Clinical Results
November 25, 2019 08:35 ET
|
La Jolla Pharmaceutical Company
SAN DIEGO, Nov. 25, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to...
La Jolla Pharmaceutical Company Announces Management Transition
November 25, 2019 08:30 ET
|
La Jolla Pharmaceutical Company
SAN DIEGO, Nov. 25, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to...
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2019 and Highlights Recent Corporate Progress
November 12, 2019 16:47 ET
|
La Jolla Pharmaceutical Company
SAN DIEGO, Nov. 12, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to...
La Jolla Pharmaceutical Company to Present at the 21st Annual H.C. Wainwright Global Investment Conference
September 05, 2019 09:00 ET
|
La Jolla Pharmaceutical Company
SAN DIEGO, Sept. 05, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to...
La Jolla Pharmaceutical Company Receives European Commission Approval for GIAPREZA™ (angiotensin II)
August 29, 2019 09:00 ET
|
La Jolla Pharmaceutical Company
SAN DIEGO, Aug. 29, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to...
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2019 and Highlights Recent Corporate Progress
August 01, 2019 08:00 ET
|
La Jolla Pharmaceutical Company
SAN DIEGO, Aug. 01, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to...
La Jolla Pharmaceutical Company Receives Orphan Designation from FDA for LJPC-0118 (Artesunate) for the Treatment of Malaria
July 23, 2019 09:00 ET
|
La Jolla Pharmaceutical Company
-Orphan Drug Designation Program offers potentially up to seven years of marketing exclusivity- -NDA Submission Planned for Fourth Quarter of 2019- SAN DIEGO, July 23, 2019 (GLOBE NEWSWIRE)...